CervoMed Inc.
CRVOCervoMed Inc. in brief
CervoMed Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. Its market value was $26 M on 30 October 2026, which makes it the 23,458th largest listed company in the world and the 4,071st largest in the USA on this site. In the year to December 2025 it had sales of $4 M and a net loss of $27 M. It employs about 15 people. Its shares trade under the symbol CRVO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About CervoMed Inc.
We are a clinical-stage biotechnology company developing treatments for age-related brain disorders. Our lead drug candidate, neflamapimod, is an investigational, orally administered small-molecule drug that readily crosses the blood brain barrier and selectively inhibits the enzyme p38α, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, our lead indication, as well as nfvPPA, RAS, and ALS.
From the company's annual report filed with the US SEC: read the report
CervoMed Inc. timeline
- 1998
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2008
- ✎Renamed Feris International, Inc.Formerly Titan Motorcycle Co Of America Inc.
- ✎Renamed Stratus Media Group, IncFormerly Feris International, Inc..
- 2014
- ✎Renamed RestorGenex CorpFormerly Stratus Media Group, Inc.
- 2016
- ✎Renamed Diffusion Pharmaceuticals Inc.Formerly RestorGenex Corp.
- 2023
- ✎Renamed CervoMed Inc.Formerly Diffusion Pharmaceuticals Inc..
- 2024
- 💰Record revenue of $10 millionFY2024, the highest of the 3 years on record.
Events of CervoMed Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,981 (Oct 2026) · #4,074 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 6.6×
- Price / book
- 1.5×
- Free cash flow yield
- -48.3%
- Net margin
- -672.6%
- Operating margin
- -705.5%
- Return on equity
- -148.0%
- Liabilities / assets
- 20.4%
- Revenue growth
- -58.8%
- R&D / revenue
- 544.1%
- Revenue per employee
- $267 K
- Profit per employee
- $-1.8 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4M | -58.8% | $-28M | $-27M | -672.6% |
| Dec 2024 | $10M | +36.4% | $-18M | $-16M | -167.2% |
| Dec 2023 | $7M | — | $-8M | $-2M | -30.4% |
| Dec 2022 | — | — | $-3M | $-6M | — |
| Dec 2021 | — | — | $-25M | $-24M | — |
| Dec 2020 | — | — | $-16M | $-14M | — |
| Dec 2019 | — | — | $-12M | $-12M | — |
| Dec 2018 | — | — | $-19M | $-18M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-23M | — | — | — | — |
| Dec 2024 | $-17M | — | — | — | — |
| Dec 2023 | $-7M | — | — | — | — |
| Dec 2022 | $-3M | — | — | — | — |
| Dec 2021 | $-15M | — | — | — | — |
| Dec 2020 | $-14M | — | — | — | — |
| Dec 2019 | $-10M | — | — | — | — |
| Dec 2018 | $-11M | — | — | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 20268-KCurrent reportResults of operations
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Oct 29, 20268-KCurrent reportRegulation FD disclosure · Other events
- Oct 14, 20268-KCurrent reportRegulation FD disclosure
- Oct 13, 20268-KCurrent reportRegulation FD disclosure · Other events
- Oct 9, 20268-KCurrent reportRegulation FD disclosure
- Sep 28, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 10, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 10, 20268-KCurrent reportResults of operations
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Aug 4, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jul 14, 20268-KCurrent reportRegulation FD disclosure · Other events
Official filings of CervoMed Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $4 M
- Operating income
- $-28 M
- Net income
- $-27 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $23 M
- Total liabilities
- $5 M
- Total equity
- $18 M
As of December-2025
Top 36 institutional investors in CervoMed Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 316,202 | 0 (0.00%) | 2.09% | $1 M | Nov 13, 2026 |
| 2 | Woodline Partners LP | 238,853 | -450,134 (-65.33%) | 1.58% | $1 M | Nov 16, 2026 |
| 3 | Sabby Management, LLC | 199,678 | -49,202 (-19.77%) | 1.32% | $1 M | Nov 13, 2026 |
| 4 | Geode Capital Management, LLC | 92,007 | +25,084 (+37.48%) | 0.61% | $0 M | Nov 6, 2026 |
| 5 | BlackRock, Inc. | 79,663 | +25,818 (+47.95%) | 0.53% | $0 M | Nov 13, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 61,516 | +25,365 (+70.16%) | 0.41% | $0 M | Nov 13, 2026 |
| 7 | Byrne Asset Management LLC | 50,050 | -1,200 (-2.34%) | 0.33% | $0 M | Oct 6, 2026 |
| 8 | Citigroup Inc | 39,334 | +38,670 (+5823.80%) | 0.26% | $0 M | Nov 4, 2026 |
| 9 | Citizens Financial Group Inc/ri | 37,477 | 0 (0.00%) | 0.25% | $0 M | Oct 23, 2026 |
| 10 | Gsa Capital Partners LLP | 29,992 | New | 0.20% | $0 M | Nov 16, 2026 |
| 11 | Savvy Advisors, Inc. | 25,922 | 0 (0.00%) | 0.17% | $0 M | Nov 12, 2026 |
| 12 | Thompson Davis & Co., Inc. | 25,900 | -3,850 (-12.94%) | 0.17% | $0 M | Nov 5, 2026 |
| 13 | State Street Corp | 20,527 | 0 (0.00%) | 0.14% | $0 M | Nov 12, 2026 |
| 14 | Summit Financial, LLC | 18,140 | 0 (0.00%) | 0.12% | $0 M | Nov 12, 2026 |
| 15 | Northern Trust Corp | 13,318 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 16 | Cetera Investment Advisers | 12,073 | -7,549 (-38.47%) | 0.08% | $0 M | Nov 13, 2026 |
| 17 | Caprock Group, LLC | 11,585 | New | 0.08% | $0 M | Nov 17, 2026 |
| 18 | NFSG Corp | 11,500 | +8,500 (+283.33%) | 0.08% | $0 M | Oct 15, 2026 |
| 19 | HighTower Advisors, LLC | 11,244 | -675 (-5.66%) | 0.07% | $0 M | Nov 10, 2026 |
| 20 | Russell Investments Group, Ltd. | 8,187 | -7,176 (-46.71%) | 0.05% | $0 M | Nov 6, 2026 |
| 21 | FMR LLC | 5,272 | -5,266 (-49.97%) | 0.03% | $0 M | Nov 10, 2026 |
| 22 | Vanguard Global Advisers, LLC | 2,597 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 23 | UBS Group AG | 2,559 | +1,567 (+157.96%) | 0.02% | $0 M | Nov 10, 2026 |
| 24 | Morgan Stanley | 2,550 | -10,149 (-79.92%) | 0.02% | $0 M | Nov 13, 2026 |
| 25 | Federation des caisses Desjardins du Quebec | 1,700 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
Show all 36: investors 26 to 36
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Osaic Holdings, Inc. | 1,517 | +1,487 (+4956.67%) | 0.01% | $0 M | Nov 12, 2026 |
| 27 | Royal Bank Of Canada | 1,353 | +1,052 (+349.50%) | 0.01% | $0 M | Nov 16, 2026 |
| 28 | Tower Research Capital LLC (TRC) | 1,318 | -855 (-39.35%) | 0.01% | $0 M | Nov 16, 2026 |
| 29 | Hoey Investments, Inc | 1,080 | 0 (0.00%) | 0.01% | $0 M | Oct 29, 2026 |
| 30 | Nuveen, LLC | 733 | New | 0.00% | $0 M | Nov 10, 2026 |
| 31 | Nisa Investment Advisors, LLC | 145 | -106 (-42.23%) | 0.00% | $0 M | Oct 20, 2026 |
| 32 | SBI Securities Co., Ltd. | 145 | -110 (-43.14%) | 0.00% | $0 M | Oct 22, 2026 |
| 33 | BNP Paribas Financial Markets | 40 | -51 (-56.04%) | 0.00% | $0 M | Nov 12, 2026 |
| 34 | Robinhood Markets, Inc. | 19 | — | 0.00% | $0 M | Nov 18, 2026 |
| 35 | Arax Advisory Partners | 5 | -12 (-70.59%) | 0.00% | $0 M | Nov 12, 2026 |
| 36 | Danske Bank A/s | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
Mutual funds holding CervoMed Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 250,174 | $1 M | 1.7% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 66,028 | $0 M | 0.44% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 37,241 | $0 M | 0.25% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 19,545 | $0 M | 0.13% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 9,020 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 8,992 | $0 M | 0.06% | <0.01% | +16% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 7,411 | $0 M | 0.05% | <0.01% | +51% | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 3,281 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,068 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at CervoMed Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Joshua S. BogerDirector, 10% owner | Buyindirect | +955,414 | $3.140 | $3.0 M | 1.80 M | Form 4 |
| filed | Matthew WintonChief Commercial and Business | Buy | +1,500 | $7.950 | $12 K | 15,000 | Form 4 |
| filed | William Robert ElderCFO, GC & Secretary | Buy | +2,500 | $8.320 | $21 K | 12,500 | Form 4 |
| filed | Matthew WintonChief Commercial and Business | Buy | +3,500 | $8.430 | $30 K | 13,500 | Form 4 |
| filed | William Robert ElderCFO, GC & Secretary | Buy | +1,000 | $8.450 | $8 K | 10,000 | Form 4 |
| filed | Sylvie GregoireDirector, 10% owner | Buy | +10,793 | $8.460 | — | 1.48 M | Form 4 |
| filed | John J. AlamCEO & President, Director, 10% owner | Buy | +10,807 | $8.460 | $91 K | 1.48 M | Form 4 |
| filed | Sylvie GregoireDirector, 10% owner | Buyindirect | +10,807 | $8.460 | — | 12,500 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: CervoMed Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-100 reverse split
Trading halts
- 2026-06-18 17:13 UTC, code LUDP, resumed 17:18 UTC
- 2026-06-18 16:56 UTC, code LUDP, resumed 17:06 UTC
- 2026-06-18 16:45 UTC, code LUDP, resumed 16:55 UTC
- 2026-06-18 16:35 UTC, code LUDP, resumed 16:45 UTC
- 2026-06-18 16:07 UTC, code LUDP, resumed 16:12 UTC
Fails to deliver
- : 2,891 shares at $1.75
- : 24,572 shares at $2.21
- : 285 shares at $2.24
- : 613 shares at $2.31
- : 1,487 shares at $2.24
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
CervoMed Inc. scorecard#
Passes 3 of the 14 checks that could be worked out: strongest in valuation (2 of 5), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.4×Price to book 1.4× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median6.6×Price to sales 6.6× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-48.3%Free cash flow is -48.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- ✗Revenue grew in the newest year-58.8%Revenue down 58.8% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$27 M-$27 M in fiscal 2025 against -$14 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$27 MNet income -$27 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-705.5%-705.5% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-93.9%-93.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities4.9×Current ratio 4.91 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-5.52Z-score -5.52 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from CervoMed Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -705.5% | -60.5% | |
| Net margin | -672.6% | -68.9% | |
| Return on equity | -93.9% | -61.0% | |
| Revenue growth | -58.8% | 15.8% |
1of 7on the Piotroski tests of financial strength
- Revenue fell 58.8% against the year before.
- Net loss of $27 million, the 16th loss-making year in a row.
CervoMed Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 4.0−58.9%100% | 9.7+36.3%100% | 7.1—100% | 0—— | — | — | — | — | — | — | |
| Research and development | 22+16.1%545% | 19+123%193% | 8.4+531%118% | 1.3r7.2−84.3%— | 8.5−9.8%— | 9.4+42.4%— | 6.6+15.1%— | 5.8+13.0%— | 5.1−29.8%— | 7.3—— | |
| General and administrative | 10+14.4%262% | 9.2+40.6%94.1% | 6.5+205%91.2% | 2.1r8.7−71.3%— | 7.4+15.5%— | 6.4+33.3%— | 4.8−21.6%— | 6.2−0.4%— | 6.2−44.2%— | 11—— | |
| Operating expenses | 32+15.5%806% | 28+87.0%287% | 15+330%209% | 3.5—— | — | — | — | — | — | — | |
| Operating income | −28—−706% | −18—−187% | −7.8—−109% | −3.5r−16—— | −25—— | −16—— | −12—— | −19—— | −11—— | −18—— | |
| Interest and finance income | 1.3−31.0%33.4% | 1.9+783%19.9% | 0.2+253%3.1% | 0.1—— | — | — | — | — | — | — | |
| Interest expense and finance costs | — | — | 0−100%0.0% | 0.0—— | — | — | — | 0.0−97.0%— | 0.1+170%— | 0.0r0.0—— | |
| Other non-operating income (expense) | 1.3−31.4%33.2% | 1.9−65.7%19.9% | 5.6—79.0% | −2.3—— | — | — | — | — | — | — | |
| Income before tax | — | — | — | −16—— | −25—— | −16—— | −11—— | −19—— | −2.4—— | −18—— | |
| Income tax | 0—0.0% | — | — | 0—— | −0.4—— | −1.7−603%— | 0.3—— | −0.4—— | −1.1—— | −0.4—— | |
| Net income attributable to shareholders | −27—−673% | −16—−167% | −2.2—−30.4% | −5.8r−16—— | −24—— | −14—— | −12—— | −18—— | −1.4—— | −18—— | |
| Earnings per share, basic | -2.98—— | -2.02—— | -0.82—— | -11.20r-7.65—— | -12.38r-0.25—— | -0.30—— | -1.76—— | -8.21—— | -3.16r-0.21—— | -1.76—— | |
| Earnings per share, diluted | — | — | — | — | — | — | — | — | -29.11r-1.94—— | -1.76—— | |
| Shares, weighted average (basic) | 9.0+12.0%— | 8.1+203%— | 2.7+414%— | 0.5—— | — | — | — | 3.2+292%— | 0.8r12−91.9%— | 10—— | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | — | 3.2+282%— | 0.8r13−91.7%— | 10—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 8.2−8.5%36.0% | 9.0+15.5%20.9% | 7.8+90.4%78.1% | 4.1r10−89.0%98.5% | 37+102%98.6% | 19+30.6%66.8% | 14+77.4%58.8% | 8.0−10.2%43.9% | 8.9+473%34.0% | 1.6—8.9% | |
| Short-term investments | 13−57.8%55.2% | 30—69.5% | 0−100%0.0% | 12—298% | 0—0.0% | — | — | — | — | — | |
| Other current assets | 0.0−90.3%0.1% | 0.2+193%0.5% | 0.1+36.0%0.7% | 0.1—1.2% | — | — | — | — | — | — | |
| Current assets | 23−46.9%100% | 43+332%100% | 10.0+140%99.9% | 4.2r23−89.0%100% | 38+101%100.0% | 19+28.2%67.7% | 15+64.3%60.8% | 8.9−7.8%49.0% | 9.7+503%37.0% | 1.6—9.2% | |
| Property, plant and equipment | — | — | — | — | 0−100%0.0% | 0.1−40.9%0.5% | 0.3−28.0%1.0% | 0.4−24.0%1.9% | 0.5+478%1.8% | 0.1—0.5% | |
| Right-of-use (leased) assets | — | — | — | — | 0−100%0.0% | 0.1−39.6%0.5% | 0.2—1.0% | — | — | — | |
| Goodwill | — | — | — | — | — | — | — | 0−100%0.0% | 6.90.0%26.5% | 6.9—39.6% | |
| Other intangible assets | — | — | — | — | — | — | — | — | — | 8.6—49.4% | |
| Total assets | 23−46.9%100% | 43+332%100% | 10.0+140%100% | 4.2r23−89.0%100% | 38+36.5%100% | 28+15.0%100% | 24+32.5%100% | 18−30.4%100% | 26+49.5%100% | 17—100% | |
| Accounts payable | 1.5−3.8%6.4% | 1.5+128%3.5% | 0.7+581%6.6% | 0.1r1.1−89.7%2.3% | 0.9+73.6%2.5% | 0.5−56.4%2.0% | 1.3+529%5.2% | 0.2−61.2%1.1% | 0.5−69.6%2.0% | 1.7—9.6% | |
| Current liabilities | 4.7+20.0%20.4% | 3.9—9.0% | — | — | 2.9+20.2%7.7% | 2.4+41.5%8.8% | 1.7+114%7.1% | 0.8−70.1%4.4% | 2.7−39.4%10.3% | 4.4—25.4% | |
| Lease liabilities (non-current) | — | — | — | — | 0−100%0.0% | 0.0−73.7%0.1% | 0.1—0.6% | — | — | — | |
| Total liabilities | 4.7+20.0%20.4% | 3.9+49.4%9.0% | 2.6−80.3%26.0% | 13r2.4+349%316% | 2.9+0.4%7.7% | 2.9−26.7%10.5% | 4.0+53.5%16.5% | 2.6−47.3%14.2% | 4.9−40.8%18.8% | 8.3—47.5% | |
| Retained earnings | −98—−427% | −71—−164% | −54—−546% | −52r−146—−1257% | −130—−344% | −106—−382% | −92—−380% | −80—−439% | −62—−235% | −60—−344% | |
| Shareholders' equity | 18−53.5%79.6% | 39+431%91.0% | 7.4—74.0% | −33r20−195%−801% | 35+40.7%92.3% | 25+23.2%89.5% | 20+29.0%83.5% | 16−26.5%85.8% | 21+131%81.2% | 9.2—52.5% | |
| Total equity | — | — | 7.4—74.0% | −33r20—−801% | −28r35−213%−73.8% | 25+23.2%89.5% | 20+29.0%83.5% | 16−26.5%85.8% | 21+131%81.2% | 9.2—52.5% | |
| Total liabilities and equity | 23−46.9%100% | 43+332%100% | 10.0+140%100% | 4.2r23−89.0%100% | 38+36.5%100% | 28+15.0%100% | 24+32.5%100% | 18−30.4%100% | 26+49.5%100% | 17—100% | |
| Shares outstanding | 9.3+6.3%— | 8.7+53.4%— | 5.7+995%— | 0.5r2.0−74.6%— | 2.0r102−96.8%— | 64+91.2%— | 33+892%— | 3.4+249%— | 1.0r15−90.6%— | 10—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | 0−100%— | 0.1−9.5%— | 0.1—— | — | — | — | — | |
| Share-based compensation | 1.4+3.1%36.2% | 1.4+245%14.4% | 0.4+22.1%5.7% | 0.3r0.9−62.8%— | 0.9+21.9%— | 0.7+42.7%— | 0.5−57.8%— | 1.2−1.5%— | 1.2−10.8%— | 1.4—— | |
| Cash from operating activities | −23—−585% | −17—−170% | −7.4—−104% | −2.6r−15—— | −15—— | −14—— | −9.9—— | −11—— | −12—— | −11—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | −0.4—— | −0.0—— | |
| Cash from investing activities | 18—452% | −29—−294% | 0—0.0% | −12−305993%— | 0.0—— | 0—— | — | — | −0.4−105%— | 8.5—— | |
| Shares issued | — | 46+5628%476% | 0.8—11.3% | 0−100%— | 31+187%— | 11—— | — | 11—— | — | — | |
| Cash from financing activities | 4.6−90.1%115% | 46+316%476% | 11—156% | 0r0.0−100%— | 33+86.1%— | 18+11.5%— | 16+62.6%— | 9.9−51.0%— | 20+1002%— | 1.8—— | |
| Change in cash | −0.8−163%−19.1% | 1.2−67.4%12.4% | 3.7—51.8% | −2.6r−27−114%— | 19+333%— | 4.3r4.3−29.9%— | 6.2—— | −0.9−112%— | 7.3—— | −0.4—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.0−99.9%100% | 0−100%— | 0−100%— | 0−100%— | 0.0*−99.6%100% | 0.3−83.4%100% | 1.8−46.6%100% | 1.9−18.3%100% | 2.2*−13.2%100% | 1.9—100% | 3.3—100% | 2.3—100% | 2.5*—100% | |
| Research and development | 19−17.8%217349% | 3.7−39.1%— | 4.3−15.4%— | 5.1+6.2%— | 5.8*−17.7%66814% | 6.0+17.9%1873% | 5.1+35.4%291% | 4.8+71.9%252% | 7.1*+148%328% | 5.1—264% | 3.8—115% | 2.8—120% | 2.9*—115% | |
| General and administrative | 10−0.2%117675% | 2.4+4.3%— | 2.4−27.8%— | 3.0+24.9%— | 2.5*+8.4%28765% | 2.3+5.2%721% | 3.3+30.0%186% | 2.4+12.0%124% | 2.3*+9.5%107% | 2.2—114% | 2.5—76.4% | 2.1—90.7% | 2.1*—84.9% | |
| Operating expenses | 29−12.4%335025% | 6.1−27.0%— | 6.7−20.2%— | 8.1+12.3%— | 8.3*−11.3%95579% | 8.4+14.1%2594% | 8.4+33.3%476% | 7.2+46.1%377% | 9.4*+89.2%435% | 7.3—378% | 6.3—191% | 4.9—211% | 5.0*—200% | |
| Operating income | −29—−334925% | −6.1—— | −6.7—— | −8.1—— | −8.3*—−95479% | −8.0—−2494% | −6.6—−376% | −5.3—−277% | −7.2*—−335% | −5.4—−278% | −3.0—−91.1% | −2.6—−111% | −2.5*—−99.6% | |
| Interest and finance income | 0.7−56.8%8065% | 0.2−34.0%— | 0.1−71.5%— | 0.1−64.0%— | 0.2*−54.7%2761% | 0.3−50.7%98.8% | 0.4−45.7%20.9% | 0.4+407%21.3% | 0.5*+349%24.6% | 0.6—33.3% | 0.7—20.6% | 0.1—3.4% | 0.1*—4.8% | |
| Other non-operating income (expense) | 0.7−56.3%8102% | 0.2−34.0%— | 0.1−70.1%— | 0.1−64.2%— | 0.2*−54.3%2799% | 0.3−50.6%98.4% | 0.4−47.2%20.4% | 0.4+407%21.3% | 0.5*+353%24.7% | 0.6—33.1% | 0.7—20.6% | 0.1—3.4% | 0.1*—4.7% | |
| Net income attributable to shareholders | −29—−326823% | −5.9—— | −6.6—— | −8.0—— | −8.1*—−92680% | −7.7—−2395% | −6.3—−356% | −4.9—−255% | −6.7*—−310% | −4.8—−245% | −2.3—−70.4% | −2.5—−107% | −2.4*—−94.9% | |
| Earnings per share, basic | — | -0.39—— | -0.64—— | -0.86—— | — | -0.84—— | -0.70—— | -0.56—— | — | -0.55—— | -0.27—— | -0.41—— | — | |
| Earnings per share, diluted | — | — | — | — | — | — | — | — | — | -0.55—— | — | — | — | |
| Shares, weighted average (basic) | 15+63.4%— | 15+63.4%— | 10+14.5%— | 9.3+6.4%— | — | 9.3+6.3%— | 9.0+2.8%— | 8.7+41.0%— | — | 8.7—— | 8.7—— | 6.2—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | — | — | — | 8.7—— | — | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.1—28.4% | 6.1−35.8%28.4% | 22+170%86.4% | 7.9−24.4%52.5% | 8.2−8.5%36.0% | 9.4+21.9%30.8% | 8.3−16.9%21.8% | 11+64.9%27.2% | 9.0+15.5%20.9% | 7.7—15.8% | 10—18.8% | 6.4—79.6% | 7.8—78.1% | |
| Short-term investments | 14—63.5% | 14−24.2%63.5% | 2.5−90.2%9.5% | 5.0−79.9%33.0% | 13−57.8%55.2% | 18−54.1%58.3% | 25−28.1%66.2% | 25—64.1% | 30—69.5% | 39—79.6% | 35—66.0% | — | 0—0.0% | |
| Other current assets | 0.2—0.7% | 0.2+202%0.7% | 0.1+146%0.4% | 0.1−29.1%0.6% | 0.0−90.3%0.1% | 0.0−33.0%0.2% | 0.0−66.7%0.1% | 0.1+297%0.3% | 0.2+193%0.5% | 0.1—0.2% | 0.1—0.2% | 0.0—0.4% | 0.1—0.7% | |
| Current assets | 21—100% | 21−30.3%100% | 26−31.7%100% | 15−60.8%100% | 23−46.9%100% | 31−37.3%100% | 38−19.5%100% | 39+384%100% | 43+332%100% | 49—99.8% | 47—89.0% | 8.0—99.6% | 10.0—99.9% | |
| Total assets | 21—100% | 21−30.3%100% | 26−31.7%100% | 15−60.8%100% | 23−46.9%100% | 31−37.4%100% | 38−28.4%100% | 39+382%100% | 43+332%100% | 49—100% | 53—100% | 8.0—100% | 10.0—100% | |
| Accounts payable | 1.6—7.6% | 1.6+19.8%7.6% | 0.7−62.8%2.6% | 2.3+22.1%15.0% | 1.5−3.8%6.4% | 1.3+24.6%4.4% | 1.8+154%4.8% | 1.9+174%4.8% | 1.5+128%3.5% | 1.1—2.2% | 0.7—1.4% | 0.7—8.5% | 0.7—6.6% | |
| Current liabilities | 4.0—18.6% | 4.0—18.6% | — | — | 4.7+20.0%20.4% | — | — | — | 3.9—9.0% | — | — | — | — | |
| Total liabilities | 4.0—18.6% | 4.0−13.6%18.6% | 3.0−34.7%11.7% | 4.5+14.1%29.8% | 4.7+20.0%20.4% | 4.6+41.7%15.0% | 4.6+44.4%12.2% | 3.9+48.2%10.2% | 3.9+49.4%9.0% | 3.2—6.6% | 3.2—6.0% | 2.7—33.3% | 2.6—26.0% | |
| Retained earnings | −118—−554% | −118—−554% | −112—−432% | −106—−699% | −98—−427% | −90—−293% | −82—−215% | −76—−196% | −71—−164% | −64—−131% | −59—−111% | −57—−712% | −54—−546% | |
| Shareholders' equity | 17—81.4% | 17−33.3%81.4% | 23−31.3%88.3% | 11−69.3%70.2% | 18−53.5%79.6% | 26−43.0%85.0% | 33−33.1%87.8% | 35+549%89.8% | 39+431%91.0% | 46—93.4% | 50r50—94.0% | 5.3—66.7% | 7.4—74.0% | |
| Total equity | — | — | — | — | — | — | — | — | — | — | — | 5.3—66.7% | 7.4—74.0% | |
| Total liabilities and equity | 21—100% | 21−30.3%100% | 26−31.7%100% | 15−60.8%100% | 23−46.9%100% | 31−37.4%100% | 38−28.4%100% | 39+382%100% | 43+332%100% | 49—100% | 53—100% | 8.0—100% | 10.0—100% | |
| Shares outstanding | 15—— | 15+63.4%— | 14+46.2%— | 9.3+6.4%— | 9.3+6.3%— | 9.3+12.1%— | 9.3+12.1%— | 8.7+41.0%— | 8.7+53.4%— | 8.3—— | 8.3—— | 6.2—— | 5.7—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 1.3−11.4%15100% | 0.3+5.4%— | 0.4−27.1%— | 0.3−3.3%— | 0.3*−11.5%3424% | 0.3+7.6%90.4% | 0.5−14.1%28.3% | 0.4+65.5%18.8% | 0.3*+105%15.6% | 0.3—14.0% | 0.6—17.6% | 0.2—9.3% | 0.2*—6.6% | |
| Cash from operating activities | −27—−304688% | −5.1*—— | −6.9*—— | −8.0—— | −6.6*—−75358% | −6.5*—−2004% | −6.5*—−371% | −3.9—−203% | −8.1*—−372% | −4.9*—−250% | −2.2*—−66.9% | −1.4—−60.7% | −2.5*—−102% | |
| Cash from investing activities | 4.6−78.9%53180% | −11*−245%— | 2.5*—— | 7.7+42.9%— | 5.4*−42.3%61583% | 7.6*+191%2350% | −0.3*—−14.5% | 5.4—281% | 9.3*—430% | 2.6*—134% | −41*—−1234% | 0—0.0% | 0*—0.0% | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from financing activities | 19+305%212801% | −0.4*—— | 19*+312%— | 0.0—— | 0*—0.0% | 0*—0.0% | 4.6*—261% | 0—0.0% | 0*—0.0% | −0.0*—−0.7% | — | — | −0.1*—−3.7% | |
| Change in cash | −3.4−299%−38707% | −16*−1569%— | 15*—— | −0.3−120%— | −1.2*−196%−13774% | 1.1*—346% | −2.2*−160%−124% | 1.5—78.3% | 1.3*—58.1% | −2.3*—−117% | 3.6*—111% | −1.4—−60.7% | −2.6*—−106% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at CervoMed Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $1.0 M | $1.5 M | $669 K | $104 |
| 2024Chief executive | $1.0 M | $953 K | $732 K | $31 |
| 2023Chief executive | $1.5 M | $1.4 M | $467 K | $101 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at CervoMed Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 1 · Material agreement 2 · Unregistered share sale 2 · Shareholder vote 1 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2017 | $16 M | Private placement after listing | $10 to $50 million | 145 | equity, options | SEC |
| Jan 2016 | $86 M | Private placement after listing | $50 to $250 million | 181 | equity | SEC |
| Apr 2014 | $25 M | Private placement after listing | $10 to $50 million | 146 | equity | SEC |
| May 2011 | $9 M | No. 2 | $2 to $10 million | 8 | equity, options | SEC |
| Apr 2011 | $3 M | No. 1 | $2 to $10 million | 73 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How CervoMed Inc. compares in Biotechnology
- Market cap$26 M · higher than 20% of 726
- Revenue$4 M · higher than 34% of 647
- Net margin-672.6% · higher than 6% of 408
- Revenue growth-58.8% · higher than 15% of 438
- Price / sales6.6× · lower than 55% of 339
- Price / book1.4× · lower than 68% of 534
- FCF yield-48.3% · higher than 25% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| CervoMed Inc.🇺🇸 | $26 M | — | -672.6% | -58.8% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at CervoMed Inc.? Verify and update this profile — free
Show CervoMed Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.